Why CVS Health (CVS) is a Top Value Stock for the Long-Term

Zacks Investment Research identifies CVS Health (CVS) as a top value stock, assigning it a Zacks Rank #2 (Buy) and an 'A' rating for both its VGM and Value Style Scores. This positive outlook is underpinned by attractive valuation metrics, including a forward P/E of 10.89, and recent upward revisions to fiscal 2025 earnings estimates by 12 analysts, raising the consensus to $6.11 per share. With an average earnings surprise of 18.1%, CVS is presented as a compelling investment opportunity for long-term value investors.

Analysis

CVS Health is positioned as a strong value investment based on the Zacks rating methodology, carrying a #2 (Buy) rank complemented by 'A' scores for both its overall VGM and specific Value styles. The company's valuation appears attractive, highlighted by a forward P/E ratio of 10.89. This positive outlook is further supported by strengthening analyst sentiment for its future earnings, evidenced by 12 upward revisions for fiscal 2025 earnings estimates within the last 60 days. These revisions have lifted the Zacks Consensus Estimate for fiscal 2025 to $6.11 per share. Furthermore, CVS has a demonstrated history of outperformance, boasting an average earnings surprise of 18.1%, which suggests a consistent ability to exceed market expectations.

Key Decisions for Investors

• Value-focused investors should consider CVS Health's forward P/E of 10.89 and 'A' Value Score as indicators of a potentially undervalued equity in the current market.
• Monitor for continued positive earnings estimate revisions, as the recent trend of 12 analysts upgrading fiscal 2025 forecasts suggests a strengthening fundamental outlook that could act as a key performance driver.
• Given the combination of a 'Buy' rating and top-tier style scores within the Zacks framework, investors who utilize quantitative, factor-based models may view CVS as a high-conviction opportunity.